One Million Patient Years of Experience in the Treatment of Multiple Sclerosis

12.04.2010 - 15:22 Uhr - . - Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) - Ongoing, prospective, clinical trial follow-up reinforces the established efficacy and safety profile of Copaxone® in patients treated for more than 19 years Teva Pharmaceutical Industries, Ltd. (NASDAQ:TEVA) announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food...